Anti-Mouse IL-1β [Clone B122] — Purified in vivo GOLD™ Functional Grade

Clone B122 is a monoclonal antibody primarily used to target mouse interleukin-1 beta (IL-1β) in in vivo mouse studies, most notably for cytokine depletion (neutralization of IL-1β activity in living animals).

Key uses in in vivo mouse studies:

• IL-1β neutralization: B122 is administered to mice to specifically neutralize the biological activity of IL-1β, allowing researchers to study the effects of IL-1β depletion on disease models (such as inflammation, infection, or autoimmune conditions).
• Cytokine depletion: It is frequently used to deplete IL-1β in living mice to examine the role of this cytokine in various physiological or pathological processes, including models of endotoxin (LPS) shock.
• Application details: B122 recognizes both precursor and mature secreted forms of mouse (and rat) IL-1β. It is suitable for use in in vivo experiments aimed at mechanistically dissecting the function of IL-1β by antibody blockade.

Other uses (not exclusive to, but also relevant in in vitro work):

• ELISA/ELISPOT capture antibody for quantifying mouse IL-1β in serum or tissue samples.
• Detection of IL-1β via Western blot or immunohistochemistry.

Summary of in vivo use:
B122 is primarily administered to living mice to block or neutralize IL-1β activity, thereby enabling experimental analysis of the consequences of IL-1β inhibition across a wide range of mouse disease and immune models.

The B122 antibody, commonly used for detecting and neutralizing mouse or rat IL-1β, is often paired with several other antibodies or proteins in the scientific literature, especially in sandwich ELISA and ELISPOT assays.

The most commonly used partner antibody with B122 is:

• Biotinylated Poly5158: In sandwich ELISA or ELISPOT assays for mouse IL-1β, B122 is typically used as the capture antibody, while biotinylated Poly5158 is used as the detection antibody.

Other commonly involved elements include:

• Recombinant IL-1β protein: Used as a standard in assays to create a standard curve for quantification.
• Secondary antibodies: Such as avidin- or streptavidin-conjugated enzymes (e.g., HRP or alkaline phosphatase) are frequently used to detect the biotinylated Poly5158 antibody in ELISA setups.

Applications and co-proteins/antibodies reported (though these are more about assay formats than specific named antibodies):

• Western blotting, Immunohistochemistry, Immunoprecipitation, and In Vivo Depletion: In these applications, B122 may be used alongside isotype controls, antibodies against other cytokines, or common cellular markers for immune cells.

In summary, the most explicit and frequent pairing in the literature is B122 with Poly5158 in ELISA or ELISPOT formats for IL-1β detection. These assays may also involve recombinant IL-1β protein standards and enzyme-conjugated detection systems. In more advanced or multiplex immunological assays, B122 could be used together with antibodies for other inflammatory cytokines or cell-type markers, tailored to the specific research question.

Clone B122 is most commonly cited in scientific literature as a monoclonal antibody that neutralizes mouse and rat interleukin-1 beta (IL-1β). Its primary research applications involve interrogating the role of IL-1β in autoimmune and inflammatory disease models.

Key findings from studies utilizing clone B122 include:

• Prevention of arthritis progression in mouse models: In collagen-induced arthritis (CIA) mouse models, intraperitoneal injection of anti-mouse/rat IL-1β (clone B122) significantly reduced the levels of plasmablasts (B220^+^CD138^+^IgG1^+) in both the spleen and peripheral blood, indicating that IL-1β neutralization by B122 dampens B cell activation and autoantibody production associated with disease progression.

• Tool for dissecting IL-1β’s immunological function: Studies using B122 in vivo demonstrate that blocking IL-1β reduces inflammatory cytokine cascades and helps clarify the pro-inflammatory role IL-1β plays in autoimmune conditions, such as rheumatoid arthritis, by limiting both cellular and humoral immune responses.

• Experimental Evidence for Efficacy: The usage of clone B122 is closely tied to statistical evidence showing that treatment groups receiving this antibody exhibit quantifiable reductions in inflammation markers (such as reduced plasmablast expansion) compared to untreated controls.

• Research Application Scope: Clone B122 is utilized specifically in murine models for functional intervention. Its effects are measured by flow cytometry of B cell subsets, arthritis disease scoring, and systemic cytokine profiling, reinforcing its specificity and efficacy for neutralizing mouse/rat IL-1β in experimental settings.

In summary, clone B122 is a validated reagent for IL-1β blockade in mouse studies, enabling detailed characterization of IL-1β-driven immune mechanisms and therapeutic evaluation in autoimmune and inflammatory models.

Dosing regimens for clone B122 (anti-IL-1β) vary depending on the disease model and study design, but the most common approaches are:

• Syngeneic tumor models: 200 µg per mouse, administered every 72 hours by intraperitoneal (i.p.) injection, typically for two to three doses or as needed per experimental timeline.
• CAR T cell-induced cytokine release syndrome or inflammatory models: 25 mg/kg for the first dose, followed by 12.5 mg/kg for subsequent daily doses, given i.p., typically for five days, starting shortly before the onset of disease or insult.

Key differences across mouse models:

• Dose (µg vs. mg/kg): Tumor studies usually use a fixed µg dose per mouse (e.g., 200 µg), while inflammatory or cytokine release syndrome models often use weight-based dosing (e.g., 25 mg/kg then 12.5 mg/kg).
• Frequency: Tumor studies often dose every three days; acute inflammatory models dose daily for a specific period (e.g., 5 days).
• Initiation timing: Some regimens start before disease challenge (prophylactic), others at the time of or after disease establishment.
• Route: Nearly all published regimens use i.p. injection for systemic effect.

These regimens are typically referenced according to the disease type and desired pharmacodynamic effect, and variations may be adapted for specific experimental endpoints.